191 related articles for article (PubMed ID: 3544789)
21. Differential antagonism by Bay k 8644, a dihydropyridine calcium agonist, of the negative inotropic effects of nifedipine, verapamil, diltiazem and manganese ions in canine ventricular muscle.
Ishii K; Taira N; Yanagisawa T
Br J Pharmacol; 1985 Feb; 84(2):577-84. PubMed ID: 2579702
[TBL] [Abstract][Full Text] [Related]
22. Coronary vasodilator compared to cardiac effects of PY 108-068, a new dihydropyridine vasodilator, on isolated, blood-perfused dog-heart preparations.
Wada Y; Satoh K; Taira N
J Cardiovasc Pharmacol; 1984; 6(5):881-7. PubMed ID: 6209495
[TBL] [Abstract][Full Text] [Related]
23. Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries.
Karasawa A; Kubo K
Jpn J Pharmacol; 1988 May; 47(1):35-44. PubMed ID: 3411819
[TBL] [Abstract][Full Text] [Related]
24. Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade.
McCall D
Circulation; 1987 Jun; 75(6 Pt 2):V3-14. PubMed ID: 2436829
[TBL] [Abstract][Full Text] [Related]
25. Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles.
Nishimura K; Miyawaki N; Yamauchi H; Iso T
Arzneimittelforschung; 1990 Mar; 40(3):244-8. PubMed ID: 2112000
[TBL] [Abstract][Full Text] [Related]
26. Comparative effects of bepridil, diltiazem, nifedipine and verapamil on haemodynamic parameters and myocardial oxygen consumption in anaesthetized dogs.
Beaughard M; Michelin MT; Tisne-Versailles J; Lamar JC
Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):276-96. PubMed ID: 3493742
[TBL] [Abstract][Full Text] [Related]
27. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
28. Vascular selectivity of seven prototype calcium antagonists: a study at the single cell level.
Pérez-Vizcaíno F; Tamargo J; Hof RP; Rüegg UT
J Cardiovasc Pharmacol; 1993 Nov; 22(5):768-75. PubMed ID: 7506331
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations.
Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K
J Cardiovasc Pharmacol; 2000 May; 35(5):741-8. PubMed ID: 10813376
[TBL] [Abstract][Full Text] [Related]
30. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
[TBL] [Abstract][Full Text] [Related]
31. [Calcium antagonists: effect on peripheral and coronary hemodynamics].
Simon R
Z Kardiol; 1984; 73 Suppl 2():79-88. PubMed ID: 6528705
[TBL] [Abstract][Full Text] [Related]
32. Comparative electrophysiologic effects of bepridil, verapamil and diltiazem in conscious and anesthetized dogs.
Kantelip JP; Alatienne M; Talmant JM; Ghyselinck N; Duchêne-Marullaz P
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):5-18. PubMed ID: 3493741
[TBL] [Abstract][Full Text] [Related]
33. Differences between negative inotropic and vasodilator effects of calcium antagonists acting on extra- and intracellular calcium movements in rat and guinea-pig cardiac preparations.
Hugtenburg JG; Mathy MJ; Boddeke HW; Beckeringh JJ; van Zwieten PA
Naunyn Schmiedebergs Arch Pharmacol; 1989 Nov; 340(5):567-75. PubMed ID: 2615848
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists.
Ohtsuka M; Ono T; Hiroi J; Esumi K; Kikuchi H; Kumada S
J Cardiovasc Pharmacol; 1983; 5(6):1074-82. PubMed ID: 6196557
[TBL] [Abstract][Full Text] [Related]
35. Effects of S-312, a new calcium antagonist, on the mechanical and electrophysiological responses of isolated cardiovascular preparations.
Ninomiya M; Tani T; Nakajima S; Ueda M
Jpn J Pharmacol; 1989 Oct; 51(2):227-38. PubMed ID: 2593380
[TBL] [Abstract][Full Text] [Related]
36. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
Opie LH
Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular profiles of the calcium antagonists nisoldipine and nifedipine in the blood-perfused dog heart.
Takahashi K; Taira N
Arzneimittelforschung; 1986 Jul; 36(7):1054-9. PubMed ID: 3768072
[TBL] [Abstract][Full Text] [Related]
38. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
Stone PH; Antman EM; Muller JE; Braunwald E
Ann Intern Med; 1980 Dec; 93(6):886-904. PubMed ID: 7004293
[TBL] [Abstract][Full Text] [Related]
39. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.
Millard RW; Lathrop DA; Grupp G; Ashraf M; Grupp IL; Schwartz A
Am J Cardiol; 1982 Feb; 49(3):499-506. PubMed ID: 6277175
[TBL] [Abstract][Full Text] [Related]
40. The effects of calcium channel blocking agents on cardiovascular function.
Low RI; Takeda P; Mason DT; DeMaria AN
Am J Cardiol; 1982 Feb; 49(3):547-53. PubMed ID: 7058766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
